Stock DIABIO DIAGONAL BIO AB
Add to a list
To use this feature you must be a member
Log inSign up

Financials Diagonal Bio AB

Equities

DIABIO

SE0015961826

Biotechnology & Medical Research

Market Closed - Nasdaq Stockholm
Other stock markets
 11:23:34 2024-04-26 am EDT 		5-day change 1st Jan Change
0.0752 SEK -5.41% Intraday chart for Diagonal Bio AB -13.96% -78.70%
Apr. 05 Diagonal Bio AB Announces the Extension of Its Partnership with Horsholm Veterinary Clinic CI
Apr. 05 Diagonal Bio AB Announces Successful Pilot Study Results CI

Valuation

Fiscal Period: December 2021 2022
Capitalization 1 81.97 10.06
Enterprise Value (EV) 1 61.21 -3.521
P/E ratio -5.28 x -0.65 x
Yield - -
Capitalization / Revenue 9.45 x 2.72 x
EV / Revenue 7.06 x -0.95 x
EV / EBITDA - -
EV / FCF -4,036,438 x 240,103 x
FCF Yield -0% 0%
Price to Book 2.42 x 1.22 x
Nbr of stocks (in thousands) 9,149 9,149
Reference price 2 8.960 1.100
Announcement Date 4/20/22 4/6/23
1SEK in Million2SEK
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2020 2021 2022
Net sales 1 7.997 8.67 3.706
EBITDA - - -
EBIT 1 -0.7773 -11.66 -15.16
Operating Margin -9.72% -134.52% -409.15%
Earnings before Tax (EBT) 1 -0.7773 -11.66 -16.16
Net income 1 -0.7773 -11.66 -16.16
Net margin -9.72% -134.52% -436.16%
EPS 2 -0.2221 -1.696 -1.702
Free Cash Flow - -15.16 -14.67
FCF margin - -174.89% -395.75%
FCF Conversion (EBITDA) - - -
FCF Conversion (Net income) - - -
Dividend per Share - - -
Announcement Date 4/20/22 4/20/22 4/6/23
1SEK in Million2SEK
Estimates

Balance Sheet Analysis

Fiscal Period: December 2020 2021 2022
Net Debt 1 - - -
Net Cash position 1 3.67 20.8 13.6
Leverage (Debt/EBITDA) - - -
Free Cash Flow - -15.2 -14.7
ROE (net income / shareholders' equity) - -54.6% -49.6%
ROA (Net income/ Total Assets) - -31.7% -27.1%
Assets 1 - 36.78 59.73
Book Value Per Share 2 4.140 3.700 0.9000
Cash Flow per Share 2 1.710 2.270 0.3900
Capex - - -
Capex / Sales - - -
Announcement Date 4/20/22 4/20/22 4/6/23
1SEK in Million2SEK
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Sector Other Biotechnology & Medical Research

1st Jan change Capi.
DIAGONAL BIO AB Stock Diagonal Bio AB
-78.70% 2.75M
IQVIA HOLDINGS INC. Stock Iqvia Holdings Inc.
+1.51% 42.75B
LONZA GROUP AG Stock Lonza Group AG
+49.22% 41.61B
MODERNA, INC. Stock Moderna, Inc.
+8.57% 41.34B
CELLTRION, INC. Stock Celltrion, Inc.
-12.36% 26.59B
ICON PUBLIC LIMITED COMPANY Stock ICON Public Limited Company
+8.92% 25.49B
ALNYLAM PHARMACEUTICALS, INC. Stock Alnylam Pharmaceuticals, Inc.
-25.13% 18.12B
MEDPACE HOLDINGS, INC. Stock Medpace Holdings, Inc.
+29.17% 12.24B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. Stock Charles River Laboratories International, Inc.
-3.12% 11.76B
UNITED THERAPEUTICS CORPORATION Stock United Therapeutics Corporation
+6.35% 11B
Other Biotechnology & Medical Research
  1. Stock Market
  2. Equities
  3. DIABIO Stock
  4. Financials Diagonal Bio AB